Vimarsana
Biggest News Aggregation in the World

Page 3 - Combination Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Combination Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Combination Therapy Today - Breaking & Trending Today

Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM - Vimarsana News

Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.

Moderna's Next-Gen COVID-19 Vaccine Passes Phase 3 Clinical Trial - Vimarsana News

Moderna's Next-Gen COVID-19 Vaccine Passes Phase 3 Clinical Trial

Biotech firm Moderna has good news for humanity. The company is preparing for its post-Covid vaccine, which will be more effective than the previous jabs.

Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma - Vimarsana News

Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.

Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors - Vimarsana News

Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors

BROOKLINE, Mass.--(BUSINESS WIRE)--Mar 25, 2024--

Emerging Agents in GVHD: Axatilimab - Vimarsana News

Emerging Agents in GVHD: Axatilimab

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.